Unique ID issued by UMIN | UMIN000047187 |
---|---|
Receipt number | R000053825 |
Scientific Title | Clinical research on [-2] proPSA measurement in a diagnosis of prostate cancer: prostate health index trial. Side study: head to head comparison between [-2] proPSA-related indices and MRI |
Date of disclosure of the study information | 2022/03/16 |
Last modified on | 2022/03/30 12:17:33 |
Clinical research on [-2] proPSA measurement in a diagnosis of prostate cancer: prostate health index trial.
Side study: head to head comparison between [-2] proPSA-related indices and MRI
Importance of [-2] proPSA measurement in a diagnosis of PROstate cancer: Prostate HEalth index Trial. Side study: head to head comparison between [-2] proPSA-related indices and MRI (PROPHET-MRI).
Clinical research on [-2] proPSA measurement in a diagnosis of prostate cancer: prostate health index trial.
Side study: head to head comparison between [-2] proPSA-related indices and MRI
Importance of [-2] proPSA measurement in a diagnosis of PROstate cancer: Prostate HEalth index Trial. Side study: head to head comparison between [-2] proPSA-related indices and MRI (PROPHET-MRI).
Japan |
prostate cancer
Urology |
Malignancy
NO
The comparison of diagnostic accuracy between [-2]proPSA-related indices and PI-RADS, which was evaluated by MRI before prostate biopsy, by using the registered data in PROPHET.
Efficacy
Comparison of diagnostic accuracy (area under ROC curve, sensitivity, specificity, positive predictive value, negative predictive value) between [-2] proPSA-related indices and MRI.
1) Risk for missing clinical significant prostate cancer in MRI-negative cases, and supplemental performance of [-2] proPSA-related indices.
2) Risk for missing clinical significant prostate cancer in cases under cutoff values of [-2] proPSA-related indices, and supplemental performance of MRI.
Observational
50 | years-old | <= |
79 | years-old | >= |
Male
1) Patients enrolled in PROPHET
2) Patients who underwent MRI before prostate biopsy
1) Patients who are intent to withdraw from the study until the date of predefined deadline
109
1st name | Kazuhiro |
Middle name | |
Last name | Suzuki |
Gunma University Graduate School of Medicine
Department of Urology
3718511
3-39-22, Showa-machi, Maebashi-city, Gunma 371-8511, Japan
027-220-8301
kazu@gunma-u.ac.jp
1st name | Kazuro |
Middle name | |
Last name | Ito |
Kurosawa Hospital
Department of Urology
370-1203
187, Yanaka-machi, Takasaki, Gunma
027-352-1166
kzito@gunma-u.ac.jp
Department of Urology, Gunma University Graduate School of Medicine
Institute for Preventive Medicine, Kurosawa Hospital
Other
Japan
Dokkyo Medical University Saitama Medical Center
Japan Community Health care Organization Tokyo Shinjuku Medical Center
Yokohama City University, Graduate School of Medicine
Kagawa University, Faculty of Medicine
Kyushu University Hospital
Nagasaki University Graduate School of Biomedical Science
The Ethics Committee of Gunma University Hospital
3-39-22, Showa-machi, Maebashi-city, Gunma 371-8511, Japan
027-220-7111
eguchi@jimu.gunma-u.ac.jp
NO
2022 | Year | 03 | Month | 16 | Day |
Unpublished
109
Open public recruiting
2022 | Year | 01 | Month | 26 | Day |
2022 | Year | 01 | Month | 27 | Day |
2022 | Year | 03 | Month | 01 | Day |
2023 | Year | 12 | Month | 31 | Day |
This additional study is expected to decrease the numbers of unnecessary prostate biopsy by comparing diagnostic accuracy between MRI and [-2]proPSA-related indices.
2022 | Year | 03 | Month | 16 | Day |
2022 | Year | 03 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053825